Shares in Idorsia fell on Monday after the Swiss pharmaceutical company proposed changes to the current terms of its bonds to avoid short-term liquidity concerns. In morning trading, shares dropped 13 ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that - in the coming days - the company intends to publish an invitation ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

Idorsia’s plans to sell its hypertension drug Tryvio have faced a speed bump, even as the biotech plows ahead with around 250 layoffs. Last month, the company said it had secured a $35 million ...

Idorsia believes signing will not be achieved in 2024. Negotiations with the undisclosed party continue, however the company cannot guarantee that an agreement can be reached. As a result ...

Idorsia plans to restructure its debt ... enough support to stage a referendum in the country, which hosts a huge pharmaceuticals sector. Swiss to vote on becoming first country to ban animal ...

Pratteln, Switzerland, January 10, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that through a share exchange it will receive the equivalent of CHF 5 million Idorsia shares which ...

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or ...

Idorsia Ltd (SIX: IDIA) today provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered ...

Idorsia Ltd has provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered exclusive negotiations ...

Idorsia Ltd (SIX: IDIA) today provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered exclusive ...